2022 NEW Drug Promotes Weight Loss Better than FDA Approved Weight Loss Drug

This video covers an experimental drug which is being clinically investigated for its effects on body weight in obese and overweight people, to date it has delivered record-breaking weight loss for participants.

DoNotAge.org 10% Discount Code: MYNMN (https://bit.ly/2VBDgNt)

Renue by Science 10% Discount Code: MYNMN (https://bit.ly/350ahYM)

I hope you enjoy my content and find it interesting or informative, hopefully both, if so, please consider supporting the channel by signing up to the one you prefer:

*Buy me a Kofi: https://ko-fi.com/mynmnexperiment
*Patreon: https://bit.ly/3hhfjl5
*Subscribestar: https://bit.ly/3psYo23

My Current Anti-Aging Protocol:
• 1.5 grams of NMN
• 1.5 grams of Trans-resveratrol
• 1.5 grams of Berberine
• 2 grams of TM
• 5,000 IU (International Units) of vitamin D3
• 120 mcg (micrograms) of vitamin K2 (Mk 7)
• 250mg Magnesium (L-Threonate)
• 200mg high molecular weight hyaluronic acid
• 2,400mg of Fisetin a day, but only on the 1st, 2nd and 3rd of each month
• 2,400mg of Quercetin a day, but only on the 1st, 2nd and 3rd of each month

https://investor.lilly.com/node/47141/pdf
https://www.advisory.com/daily-briefing/2022/05/02/tirzepatide
https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or
https://jamanetwork.com/journals/jama/article-abstract/2788781
https://www.forbes.com/sites/joshuacohen/2022/05/01/eli-lillys-weight-loss-drug-tirzepatide-shows-promising-phase-3-results-if-approved-next-hurdle-would-be-reimbursement/?sh=22d3142e66ba

Tirzepatide, a compound developed by American pharmaceutical company Eli Lilly, is a once-weekly injection that promotes weight loss by mimicking the effects of natural hormones called incretins. These hormones lower blood sugar after we eat, in addition to regulating metabolic processes related to digestion. In the case of tirzepatide, the drug is a synthetic combination of two particular incretins, they are:
o GLP-1 (glucagon-like peptide-1), and
o GIP (glucose-dependent insulino-tropic polypeptide).
GLP-1 is the basis of the anti-diabetes medication Semaglutide, which was approved by the FDA as a weight-loss drug in 2021, representing the first time the FDA had endorsed a new treatment for weight loss in several years.
The FDA approval was granted on the back of results described as a 'game-changer' for weight loss, you may remember I posted a video on the study in July 2021, but it looks like tirzepatide's formulation, thanks to the addition of GIP alongside GLP-1, may well change the game again. In Phase 3 results from the ongoing clinical trial researchers’ enrolled 2,539 participants who were either overweight or obese and who had one weight-related comorbidity, but without type 2 diabetes.
The participants received tirzepatide or a placebo for 72 weeks, along with support to follow a reduced-calorie diet and increase their levels of physical activity.
Now I have say surely a reduced calorie diet and extra exercise over 72 weeks (that’s a year and a half), alone would have had an effect! And any weight loss cannot be contributed solely to the drug, let me know what you think. Tirzepatide was administered at a dose of either 5, 10, or 15 milligrams in the weekly injection. All three groups saw significant levels of weight loss over the course of the study.
The highest dose group (15 mg per week), saw an average weight reductions of 22.5 percent of their body weight (24 kg or 52 lb),
The 10 mg a week dosage group achieved 21.4 percent weight loss (22 kg or 49 lb)
The 5 mg group saw a 16 percent body weight reduction (16 kg or 35 lb).
By comparison, the placebo group only lost 2.4 percent of their body weight (2 kg or 5 lb), I have to say that after 1.5 years of a reduced calorie diet and extra exercise, and no weight loss drug, I would expect to lose a lot more than 5lb! Previously, the semaglutide weight loss trial participates averaged roughly a 17% weight loss.
Clinical research physician Jeffrey Emmick MD, the vice president of product development at Lilly and Company said "Tirzepatide is the first investigational medicine to deliver more than 20 percent weight loss on average in a phase 3 study."
DISCLAIMER: This video and description contain discount codes, which means that if you use the code, I will receive a small commission.

FAIR-USE COPYRIGHT DISCLAIMER
Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, commenting, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational, or personal use tips the balance in favor of fair use.
#DietDrug #Tirzepatide #Semaglutide